The Phase III trial is evaluating the gene therapy, OCU400, in retinitis pigmentosa patients with RHO gene mutations and in a gene-agnostic cohort.
Precision Medicine Online
Book and Periodical Publishing
New York, New York 14,228 followers
Precision Medicine Online covers the adoption of precision medicine in all disease areas.
About us
Precision Medicine Online is published by GenomeWeb, an independent online news organization based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and diagnostics. GenomeWeb is a business unit of Crain Communications. Precision Medicine Online launched in 2023 as an expansion of Precision Oncology News, which was created in 2019 to cover the application of genomic sequencing and other biomarker-driven approaches to guide cancer treatment. While oncology has led the way in adopting molecularly informed approaches to diagnostics, monitoring, and treatment, GenomeWeb is committed to informing our readers about the adoption of precision medicine in all disease areas, and this relaunch reflects this broader scope of coverage. Our dedicated online newsroom tracks the industry players and healthcare systems driving the adoption of precision medicine in oncology, rare disease, cardiovascular disease, autoimmune disease, pharmacogenomics, and more; regulatory, policy, legal, and ethical issues affecting the field; and the challenges of implementing precision medicine as the standard of care.
- Website
-
https://www.precisionmedicineonline.com/
External link for Precision Medicine Online
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Headquarters
- New York, New York
- Founded
- 2019
Updates
-
The firm was cleared to begin the Phase I/II ATALANTA-1 trial studying GLP5101, which is currently ongoing in Europe.
Galapagos to Begin US Trial for CAR T-Cell Therapy in Non-Hodgkin Lymphoma
precisionmedicineonline.com
-
News items for the week of Aug. 19, 2024.
In Brief This Week: BMS, AstraZeneca, Daiichi Sankyo, Opus Genetics, Mindera Health
precisionmedicineonline.com
-
The approval was based on results from the Phase III THOR study, which compared Balversa to chemotherapy.
J&J's Balversa Approved in Europe for FGFR3-Mutant Bladder Cancer
precisionmedicineonline.com
-
The change allows additional cell deliveries to be made to achieve the target minimal dosage among patients who otherwise would have been ineligible.
FDA Approves Protocol Amendment for BioCardia's CardiAMP Heart Failure II Trial
precisionmedicineonline.com
-
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
precisionmedicineonline.com
-
The plan, announced in January, would reclassify many Class III in vitro diagnostic devices as Class II, impacting companion diagnostic and infectious disease tests.
FDA IVD Reclassification Plan May Reduce Regulatory Burden for Test Developers, But Questions Remain
precisionmedicineonline.com
-
In a partnership with OpenAI, Color Health has developed its Copilot software to create screening plans as well as pretreatment workups for cancer patients.
Color Health Aims to Help Doctors Create Patient-Specific Cancer Testing Plans
precisionmedicineonline.com
-
Patients with KRAS G12C-mutated non-small cell lung cancer receiving Dupert lived nearly 10 months without disease progression or death.
China's NMPA Approves Innovent KRAS G12C Inhibitor
precisionmedicineonline.com
-
After considering the data on Leqembi, the agency found that the four-to-six month slowing of disease progression wasn't enough benefit to justify its costs.
NICE Doesn't Recommend Biogen, Eisai's Alzheimer's Drug in Draft Guidance Despite MHRA Nod
precisionmedicineonline.com